RECURRENT HIGH GRADE B-CELL LYMPHOMA
Clinical trials for RECURRENT HIGH GRADE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HIGH GRADE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HIGH GRADE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can shrink tumors in people with diffuse large B-cell lymphoma that has relapsed or become resistant. The study will enroll 36 adults and measure how many patients respond and…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug may help more patients get Life-Saving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving the drug odronextamab before CAR-T cell therapy can help control aggressive large B-cell lymphomas that have returned or not responded to prior treatment. About 27 adults will receive odronextamab to slow disease progression and increase the chance…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take on HIV-Linked cancers in first human trial
Disease control Recruiting nowThis study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC